Eli Lilly signed an agreement with Cipla , allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a ...

Eli Lilly's rival Novo Nordisk plans to retail both Ozempic and Wegovy in India as diabetes and weight-loss drugs, respectively.| Business News ...

Indian pharma giant Cipla on Thursday announced an agreement with US pharmaceutical firm Eli Lilly, acquiring the rights to ...

Analysts say that while the deal is a positive for the stock, it has already been priced in and investors are now resorting ...

In an exciting collaboration, Cipla and Eli Lilly have unveiled Yurpeak, a groundbreaking diabetes and weight management ...

Under the agreement, Eli Lilly will continue to market tirzepatide under brand name Mounjaro, while Cipla will have the ...

Cipla will market Eli Lilly’s diabetes and weight-loss drug Mounjaro as Yurpeak in India, enhancing accessibility and ...

In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) ...

Cipla shares drop 3.7% after Eli Lilly deal, but analysts see strong growth in India's obesity market—learn more about the ...

Mumbai, Oct. 24 -- "The introduction of a second brand of Tirzepatide in India through our commercial agreement with Cipla ...

Eli Lilly ( NYSE: LLY) has partnered with India's Cipla to market its weight-loss medication Tirzepatide under a new brand in ...

Under the agreement, Cipla will market the drug under a new brand name, Yurpeak, while Lilly continues to sell it as Mounjaro ...